Development of a radioimmunoassay for some agonists of growth hormone-releasing hormone

K. Groot, V. J. Csernus, J. Pinski, J. Zsigo, Z. Rekasi, M. Zarandi, A. V. Schally

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

A radioimmunoassay (RIA) method was developed for determination of superactive GH-RH agonist Dat1,Ala15,Nle27 GH-RH(1-28)Agm29 (MZ-2-51) and some of the related analogs in biological fluids. The analogs were radioiodinated using the Bolton-Hunter method. For the generation of antibodies, rabbits were immunized with MZ-2-51 and its C-terminal derivative Nle27 GH-RH(17-28)Agm29, conjugated to bovine serum albumin with glutaraldehyde. The resulting antibodies exhibited high affinity and very low cross-reactivity with related, naturally occurring peptides, enabling us to set up a sensitive and specific RIA. High cross-reactions with some of the MZ-2-51 derivatives like MZ-3-149 (40%) and related compounds made it possible for us to also assay these analogs with the same antibody. At B/Bo of 23-37%, the final dilutions of the antibodies ranged from 1:35,000 to 1:120,000. The minimal detectable concentration of MZ-2-51 was 1.4 fmol (4.6 pg)/tube. The intra- and inter-assay variations were 2.2-4.1% and 9.3-13.9%, respectively. The antibody permitted direct determination of the analogs, without extraction, from biological fluids and tissue extracts. The analogs proved to be stable in serum, and no special treatment of sample was required. Pharmacodynamic studies were performed in rats. Serum levels of GH-RH(1-29) and two of its analogs were monitored following subcutaneous injection. Serum concentration of the analogs and GH-RH(1-29) reached a peak 15 min after injection and returned to basal level within 90-120 min. Serum GH levels also reached a peak in 15 min, but declined more slowly in the case of analogs than GH-RH(1-29). The biological half-life of both analogs were significantly longer than that of GH-RH (1-29), probably due to their reduced enzymatic degradation.

Original languageEnglish
Pages (from-to)162-168
Number of pages7
JournalInternational Journal of Peptide and Protein Research
Volume41
Issue number2
Publication statusPublished - 1993

Fingerprint

Growth Hormone-Releasing Hormone
Radioimmunoassay
Antibodies
Assays
Serum
Pharmacodynamics
Derivatives
Tissue Extracts
Fluids
Cross Reactions
Glutaral
Subcutaneous Injections
Bovine Serum Albumin
Dilution
Half-Life
Rats
Rabbits
Degradation
Peptides
Injections

ASJC Scopus subject areas

  • Biochemistry

Cite this

Development of a radioimmunoassay for some agonists of growth hormone-releasing hormone. / Groot, K.; Csernus, V. J.; Pinski, J.; Zsigo, J.; Rekasi, Z.; Zarandi, M.; Schally, A. V.

In: International Journal of Peptide and Protein Research, Vol. 41, No. 2, 1993, p. 162-168.

Research output: Contribution to journalArticle

@article{f3b54a1934254b579ed74f282801dca4,
title = "Development of a radioimmunoassay for some agonists of growth hormone-releasing hormone",
abstract = "A radioimmunoassay (RIA) method was developed for determination of superactive GH-RH agonist Dat1,Ala15,Nle27 GH-RH(1-28)Agm29 (MZ-2-51) and some of the related analogs in biological fluids. The analogs were radioiodinated using the Bolton-Hunter method. For the generation of antibodies, rabbits were immunized with MZ-2-51 and its C-terminal derivative Nle27 GH-RH(17-28)Agm29, conjugated to bovine serum albumin with glutaraldehyde. The resulting antibodies exhibited high affinity and very low cross-reactivity with related, naturally occurring peptides, enabling us to set up a sensitive and specific RIA. High cross-reactions with some of the MZ-2-51 derivatives like MZ-3-149 (40{\%}) and related compounds made it possible for us to also assay these analogs with the same antibody. At B/Bo of 23-37{\%}, the final dilutions of the antibodies ranged from 1:35,000 to 1:120,000. The minimal detectable concentration of MZ-2-51 was 1.4 fmol (4.6 pg)/tube. The intra- and inter-assay variations were 2.2-4.1{\%} and 9.3-13.9{\%}, respectively. The antibody permitted direct determination of the analogs, without extraction, from biological fluids and tissue extracts. The analogs proved to be stable in serum, and no special treatment of sample was required. Pharmacodynamic studies were performed in rats. Serum levels of GH-RH(1-29) and two of its analogs were monitored following subcutaneous injection. Serum concentration of the analogs and GH-RH(1-29) reached a peak 15 min after injection and returned to basal level within 90-120 min. Serum GH levels also reached a peak in 15 min, but declined more slowly in the case of analogs than GH-RH(1-29). The biological half-life of both analogs were significantly longer than that of GH-RH (1-29), probably due to their reduced enzymatic degradation.",
author = "K. Groot and Csernus, {V. J.} and J. Pinski and J. Zsigo and Z. Rekasi and M. Zarandi and Schally, {A. V.}",
year = "1993",
language = "English",
volume = "41",
pages = "162--168",
journal = "International Journal of Peptide and Protein Research",
issn = "0367-8377",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Development of a radioimmunoassay for some agonists of growth hormone-releasing hormone

AU - Groot, K.

AU - Csernus, V. J.

AU - Pinski, J.

AU - Zsigo, J.

AU - Rekasi, Z.

AU - Zarandi, M.

AU - Schally, A. V.

PY - 1993

Y1 - 1993

N2 - A radioimmunoassay (RIA) method was developed for determination of superactive GH-RH agonist Dat1,Ala15,Nle27 GH-RH(1-28)Agm29 (MZ-2-51) and some of the related analogs in biological fluids. The analogs were radioiodinated using the Bolton-Hunter method. For the generation of antibodies, rabbits were immunized with MZ-2-51 and its C-terminal derivative Nle27 GH-RH(17-28)Agm29, conjugated to bovine serum albumin with glutaraldehyde. The resulting antibodies exhibited high affinity and very low cross-reactivity with related, naturally occurring peptides, enabling us to set up a sensitive and specific RIA. High cross-reactions with some of the MZ-2-51 derivatives like MZ-3-149 (40%) and related compounds made it possible for us to also assay these analogs with the same antibody. At B/Bo of 23-37%, the final dilutions of the antibodies ranged from 1:35,000 to 1:120,000. The minimal detectable concentration of MZ-2-51 was 1.4 fmol (4.6 pg)/tube. The intra- and inter-assay variations were 2.2-4.1% and 9.3-13.9%, respectively. The antibody permitted direct determination of the analogs, without extraction, from biological fluids and tissue extracts. The analogs proved to be stable in serum, and no special treatment of sample was required. Pharmacodynamic studies were performed in rats. Serum levels of GH-RH(1-29) and two of its analogs were monitored following subcutaneous injection. Serum concentration of the analogs and GH-RH(1-29) reached a peak 15 min after injection and returned to basal level within 90-120 min. Serum GH levels also reached a peak in 15 min, but declined more slowly in the case of analogs than GH-RH(1-29). The biological half-life of both analogs were significantly longer than that of GH-RH (1-29), probably due to their reduced enzymatic degradation.

AB - A radioimmunoassay (RIA) method was developed for determination of superactive GH-RH agonist Dat1,Ala15,Nle27 GH-RH(1-28)Agm29 (MZ-2-51) and some of the related analogs in biological fluids. The analogs were radioiodinated using the Bolton-Hunter method. For the generation of antibodies, rabbits were immunized with MZ-2-51 and its C-terminal derivative Nle27 GH-RH(17-28)Agm29, conjugated to bovine serum albumin with glutaraldehyde. The resulting antibodies exhibited high affinity and very low cross-reactivity with related, naturally occurring peptides, enabling us to set up a sensitive and specific RIA. High cross-reactions with some of the MZ-2-51 derivatives like MZ-3-149 (40%) and related compounds made it possible for us to also assay these analogs with the same antibody. At B/Bo of 23-37%, the final dilutions of the antibodies ranged from 1:35,000 to 1:120,000. The minimal detectable concentration of MZ-2-51 was 1.4 fmol (4.6 pg)/tube. The intra- and inter-assay variations were 2.2-4.1% and 9.3-13.9%, respectively. The antibody permitted direct determination of the analogs, without extraction, from biological fluids and tissue extracts. The analogs proved to be stable in serum, and no special treatment of sample was required. Pharmacodynamic studies were performed in rats. Serum levels of GH-RH(1-29) and two of its analogs were monitored following subcutaneous injection. Serum concentration of the analogs and GH-RH(1-29) reached a peak 15 min after injection and returned to basal level within 90-120 min. Serum GH levels also reached a peak in 15 min, but declined more slowly in the case of analogs than GH-RH(1-29). The biological half-life of both analogs were significantly longer than that of GH-RH (1-29), probably due to their reduced enzymatic degradation.

UR - http://www.scopus.com/inward/record.url?scp=0027458399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027458399&partnerID=8YFLogxK

M3 - Article

C2 - 8458690

AN - SCOPUS:0027458399

VL - 41

SP - 162

EP - 168

JO - International Journal of Peptide and Protein Research

JF - International Journal of Peptide and Protein Research

SN - 0367-8377

IS - 2

ER -